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Abstract
Background: Monitoring plasma gentamicin concentrations in neonates 24 hours after a once
daily dose (4 mg/kg) often necessitates additional blood sampling. In adults a nomogram has been
developed enabling evaluation of gentamicin doses by sampling concentrations with other blood
tests, 4 – 16 hours after administration. We attempted to develop a similar nomogram for
neonates.
Methods:  In addition to standard 24 hour sampling to monitor trough concentrations, one
additional "random" gentamicin concentration was measured in each of 50 neonates <4 days of age
(median gestation 33 weeks [28–41]), when other blood samples were clinically necessary, 4 – 20
hours after gentamicin administration. 24 hour concentrations of >1 mg/L were considered high,
and an indication to extend the dosing interval.
Results: Highest correlation (r2 = 0.51) of plasma gentamicin concentration against time (4 to 20
hours) was with logarithmic regression. A line drawn 0.5 mg/L below the true regression line
resulted in all babies with 24 hr gentamicin concentrations >1 mg/L having the additional "random"
test result above that line, i.e. 100% sensitivity for 24 hour concentrations>1 mg/L, though only 58%
specificity. Having created the nomogram, 39 further babies (median gestation 34 weeks [28–41]),
were studied and results tested against the nomogram. In this validation group, sensitivity of the
nomogram for 24 hr concentrations >1 mg/L was 92%; specificity 14%, positive predictive value
66%, and negative predictive value 50%.
Prematurity (≤ 37 weeks) was a more sensitive (94%) and specific (61%) indicator of high 24-hour
concentrations. 62 (87%) of 71 preterm babies had high 24-hour concentrations.
Conclusion: It was not possible to construct a nomogram to predict gentamicin concentrations
at 24 hours in neonates with a variety of gestational ages. Dosage tailored to gestation with
monitoring of trough concentrations remains management of choice.
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Background
Aminoglycosides are widely considered to be the treat-
ment of choice in newborn infants with suspected or
proven sepsis. Gentamicin remains one of the most com-
monly used aminoglycosides [1]. It is usually given in
combination with a β-lactam antibiotic to provide opti-
mum cover against organisms most frequently responsi-
ble for infections during the neonatal period. However, a
significant drawback in the use of aminoglycosides is their
narrow therapeutic index, the potential for ototoxicity and
nephrotoxicity and the need for monitoring of drug con-
centrations. In many cases, antibiotics are given to high-
risk infants until infection is excluded, rather than to treat
proven sepsis. Such courses may only last 48 hours or
until the cultures are definitely negative and therefore
early measurement of levels is preferable if a safe dosing
regimen is to be achieved.
The search for the safest and most effective regimen for
gentamicin administration in the newborn has led to
exploration of varied doses and dosing intervals [2]. Sug-
gested doses have ranged from 2 to 5 mg/kg/dose, given
every 8–36 hours with target trough concentrations of
0.5–2 mg/L [3].
Traditionally, infants received multiple daily doses of gen-
tamicin. There has been a move towards high dose, long
interval treatment with once daily administration in
adults [3-7]. This approach has been adopted in view of
the improved efficacy achieved with higher peak concen-
trations, the prolonged duration of the post-antibiotic
effect and similar or lower incidence of toxicity when
compared with traditional dosing [3,6]. It has been shown
to be a cost-effective method and more convenient than
multiple administration [8].
Once daily aminoglycosides are also used in neonates [9].
However because of the long half-life of aminoglycosides
in neonates this once daily regimen is more like steady
state dosing achieved by 8 hourly dosing in adults. Our
unit moved to once daily dosage some years ago.
This in turn presented the problem of finding the most
appropriate way of monitoring to avoid nephrotoxicity
and ototoxicity [10]. Third dose monitoring is commonly
used, but this does not allow early modification of dose or
time interval if high concentrations are detected, particu-
larly in those babies given once daily aminoglycosides
who might have only a short 48 hour course of treatment
before negative cultures are confirmed. Monitoring before
the third dose will thus be when the drug is being discon-
tinued.
A nomogram has been developed for use in adults receiv-
ing once-daily gentamicin. This allows evaluation of gen-
tamicin concentrations by sampling at any time between
6 and 14 hours after administration, to predict whether or
not it is safe to give the next antibiotic dose [11]. If such a
nomogram were available for use in the newborn it would
have a number of advantages: avoiding potentially toxic
concentrations of gentamicin with the second dose;
avoiding delay in giving the second dose; reducing the
number of needlesticks for infants by taking samples with
other necessary blood tests; being able to process most
samples during normal working hours; and avoiding the
need for 24 hour trough samples.
Aim of the study
The aim of this study was to develop and validate a simple
and user-friendly nomogram to predict 24 hour trough
concentrations reliably across a range of gestational ages,
allowing modification of the dose at the earliest opportu-
nity. We hypothesised that it would be possible to predict
24 hour trough concentrations from a single convenience
sample taken between 4 and 20 hours after the first dose.
Methods
The study included infants of birth weight ≥ 1000 g admit-
ted to the Neonatal Unit of Birmingham Heartlands Hos-
pital within the first four days of life, with increased risk
for, suspected or proven sepsis. Infants received gen-
tamicin 4 mg/kg once daily. Trough gentamicin concen-
trations were taken at 24 hours after the first dose, before
a steady state was reached. For this reason, we aimed to
achieve trough gentamicin concentrations of ≤ 1 mg/L.
Clinical decisions about dosage alteration were based on
this concentration. Infants <1000 g do not routinely
receive aminoglycosides on our unit.
1 mg/l or less was considered as an acceptable trough gen-
tamicin concentration. A second additional "random"
sample for gentamicin concentration was taken from each
baby between 4 and 20 hours after the first antibiotic
dose, at a time when a blood sample was required for
other clinical reasons. The additional sample was not truly
"random" as its timing was dictated by the need for other
blood tests, but nevertheless we have used the word "ran-
dom" to signify this test and its results. Infants whose cre-
atinine levels rose after birth or who had suffered birth
asphyxia (requiring resuscitation for more than 10 min-
utes) were excluded from the study since they may have
abnormal renal function.
Gentamicin concentrations were measured using a fluo-
rescence polarization immunoassay (Abbott TDx, Abbott
Laboratories, Queenborough, Kent, UK), with reagents
supplied by Biostat Diagnostics Systems (Biostat Ltd,
Stockport, Cheshire, UK).BMC Pediatrics 2006, 6:8 http://www.biomedcentral.com/1471-2431/6/8
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Results from this derivation cohort of 50 babies were used
to create a nomogram. A second cohort of babies was then
recruited for validation of the nomogram.
Ethical approval for this research was obtained from the
East Birmingham Research Ethics Committee. Verbal con-
sent was obtained from parents of all the infants included
in the study.
Results
Derivation cohort
Fifty babies with a median gestation of 33 weeks (range 28
– 41 weeks), and birth weight 2314 (1160 – 4640) grams,
had a single "random" blood sample taken between 4 and
20 hours post gentamicin administration as well as a sam-
ple at 24 hours for trough gentamicin concentration.
Figure 1 shows the results. Thirty-one of the 50 babies had
a 24 hr trough gentamicin concentration > 1 mg/L. The
best regression of "random" gentamicin concentration
against time after first dose for all 50 babies was logarith-
mic, with a regression coefficient (r) of 0.71 (95% CI 0.54,
0.83).
Nine of the 31 babies with 24 hour trough gentamicin lev-
els >1 mg/l had a "random" concentration below the
regression line. If this regression line were to be used as
the cut off for predicting 24 hour concentrations, its sen-
sitivity would be 84% (16/19), positive predictive value
64% (16/25) and specificity 71% (22/31). However, as
the purpose of the nomogram would be to predict babies
with gentamicin concentrations at 24 hours of <1 mg/l
(ie. those babies who could be given a second dose with-
Derivation Cohort: "Random" Gentamicin Concentration v Time Figure 1
Derivation Cohort: "Random" Gentamicin Concentration v Time. The equation is given for the regression line which 
is the heavier of the two lines on the graph. The cut off line is the lighter and lower line (see Text). Safe 24 hr concentration = 
≤ 1 mg/l. High 24 hr concentration = >1 mg/l.
y = -1.43Ln(x) + 5.72
R
2 = 0.51
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out waiting for a 24 hour trough result), the positive pre-
dictive value of the cut off line would need to be 100%. To
achieve this, the cut off line was drawn parallel to, but 0.5
mg/l below the regression line. All the babies with high
24-hour concentrations then had "random" values above
this cut off line, i.e. its positive predictive value for babies
with 24 hour concentrations <1 mg/l was 100%. How-
ever, 8 of the 19 babies with 24 hour gentamicin concen-
trations <1 mg/l were above this line, giving a sensitivity
of only 58%.
Validation cohort
To see if this cut off line could be used to predict 24 hour
gentamicin concentrations <1 mg/l consistently, a further
39 babies had "random" and 24 hour gentamicin assays
taken as described above. Their median (range) gestation
was 34 (28–41) weeks, and birth weight 2380 (1120–
4080) grams, not significantly different from the deriva-
tion cohort. Figure 2 shows the results against the cut off
line. The sensitivity of the cut off line was 92% (23/25),
specificity 14% (2/14), positive predictive value 66% (23/
Validation Cohort: "Random" Gentamicin Concentration v Time Figure 2
Validation Cohort: "Random" Gentamicin Concentration v Time. "Random" gentamicin concentrations from 39 vali-
dation babies plotted against the cut off line derived from Figure 1 (see Text). Safe 24 hr concentration = ≤ 1 mg/l. High 24 hr 
concentration = >1 mg/l.
0
1
2
3
4
5
6
0 5 10 15 20 25
Hours
G
e
n
t
a
m
i
c
i
n
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
)
m
g
/
L
)
Safe 24 hour concentration
High 24 hour concentration
Log. (Series1) Cut off lineBMC Pediatrics 2006, 6:8 http://www.biomedcentral.com/1471-2431/6/8
Page 5 of 7
(page number not for citation purposes)
35) and negative predictive value 50% (2/4). Had the
original regression line been used, the sensitivity would
have been 50% and the positive predictive value 47%.
Analysis by gestation
As the nomogram failed to be a useful predictor of trough
gentamicin concentrations <1 mg/l, we re-analysed the
data. Table 1 shows the 24-hour gentamicin concentra-
tion against gestation for all 89 babies. A trough gen-
tamicin level <1 mg/l was significantly associated with
increasing gestational age (P < 0.0001 by χ2). Table 2
shows the performance characteristics for predicting
trough gentamicin concentrations <1 mg/l for the nomo-
gram and for gestational age. Even in term babies (> 37
weeks), using gestation as a 'test' for 24 hour gentamicin
levels <1 mg/l after a dose of 4 mg/Kg would only have a
positive predictive value of 78% (14/18). With only 6% of
babies less than 33 weeks having a 24 hour gentamicin
concentration <1 mg/l, it is apparent that the dosing inter-
val would need to be extended for the lowest gestations,
and, in some cases, right up to 37 weeks.
Discussion
There is increasing support for the use of once daily
aminoglycosides in adults and children [12]. Monitoring
of once-daily aminoglycoside therapy in adults can now
be done using a single serum level taken 6 to 14 hours
after the aminoglycoside dose [11,13]. In adults with nor-
mal renal function this can be done using a nomogram.
We were unable to make a similar, clinically useful nom-
ogram to predict trough aminoglycoside concentrations
for infants receiving once-daily gentamicin. In our study,
gestational age was a better predictor of trough aminogly-
coside concentration.
Many factors may influence trough aminoglycoside levels
in neonates (gestational age, volume of distribution,
clearance and half life). The most important seem to be
gestational age and dose interval [10,14,15]. Chronologi-
cal age with maturation of renal function and changes in
body composition after birth may also be important
[2,16]. We only studied infants in the first 4 days of life
and excluded those below 1000 grams. However there
was still a marked variation in gentamicin concentrations
in these infants. We had expected that this variation in
function would not affect the development of the nomo-
gram, in that babies with good renal clearance of gen-
tamicin would have had a "random" concentration below
the cut off line and a 24 concentration < 1 mg/L. Equally
those with less good renal function would have had a
lower clearance of gentamicin and high "random" and 24
hour concentrations. Theoretically this should have dealt
with variations in renal function due to gestation, postna-
tal age and disease. This proved not to be so.
Given the variation in aminoglycoside concentrations, it
might be suggested that a larger number of subjects
should have been studied to derive our nomogram. How-
ever the adult nomogram was devised using only 20
patients, 14 of whom had normal renal function [11]. The
adult nomogram was then validated on a further 57
patients. Our study shows the importance of validating
nomograms for once-daily aminoglycoside use for each
group of patients.
A "safe" trough aminoglycoside concentration in those
receiving once-daily dosing has not yet been clearly
defined, especially in neonates [2]. There is little evidence
to support the presently accepted "therapeutic range" in
adults on multiple daily doses [17], and even less evi-
dence in neonates [18]. In once-daily dosing in adults,
some authors suggest trough concentrations of less than 2
mg/L are acceptable [11], whilst others suggest less than 1
mg/L [13]. We chose to use a concentration 1 mg/L or less
as an acceptable trough in our study, because we were
measuring concentrations after the first dose. The elimina-
Table 1: Proportion of trough gentamicin levels <1 mg/l in neonates given once daily gentamicin, by gestation.
Gestation (completed weeks) n 24 hour gentamicin concentration <1 mg/l (%)
28 – 32 31 2 (6)
33 – 37 40 17 (42)
>37 18 14 (78)
Table 2: Performance characteristics of nomogram for predicting safe trough gentamicin levels (<1mg/l) in neonates given once daily 
gentamicin (4mg/kg)
n Sensitivity (%) Specificity (%) Positive Predictive 
Value (%)
Negative Predictive 
Value (%)
Derivation 50 100 58 79 100
Validation 39 92 14 66 50
Gestation >37 weeks 89 94 61 78 87BMC Pediatrics 2006, 6:8 http://www.biomedcentral.com/1471-2431/6/8
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tion of aminoglycosides in neonates is much slower than
in adults, so accumulation of the drug will occur even
with once-daily dosing. Results after a single dose will
therefore be different from those obtained at a steady
state. This low trough concentration therefore allows for
accumulation of gentamicin with subsequent doses.
When should trough aminoglycoside levels be measured
in neonates on once daily regimens? Measuring levels
before the second dose will allow early identification of
those at risk of possible toxicity and appropriate alteration
in dose. If levels are not measured until before the third
dose many neonates on 24 or 36 hourly dosing regimens
will have stopped the antibiotic before this level is due.
This result will thus be of little use.
Some suggest that it may not be necessary to measure lev-
els in neonates given aminoglycosides once daily for 48
hours [2]. However given the variation in levels seen in
our study it would seem prudent to measure levels on all
neonates given aminoglycosides [19].
One implication of our study is that, for neonates below
32 weeks gestation receiving gentamicin 4 mg/kg, the dos-
ing interval should be greater than 24 hours. Other
authors have suggested this [7,15], but studies confirming
the safety and efficacy of these doses in preterm infants are
necessary. Clinical practice on our neonatal unit has
changed, so that infants of less than 32 weeks gestation
now receive gentamicin every 36 hours. The other impli-
cation is that all neonates need to have aminoglycoside
concentrations measured because of the marked individ-
ual variation of results.
When suitable dosing regimens for once-daily aminogly-
cosides have been designed for preterm infants, it may be
possible to construct nomograms to allow monitoring by
"random" levels. This will require a larger number of
infants to produce a number of nomograms for different
gestations and postnatal ages or a nomogram with more
than one cut-off line. Alternatively a multiple regression
model using other factors might be needed. However we
wanted to develop a simple nomogram for all infants.
Previous nomograms designed to aid gentamicin dosing
in neonates have either failed to achieve gentamicin levels
in the target range [20] or not been validated [21]. We
were unable to construct a single, clinically useful nomo-
gram to predict aminoglycoside concentrations for infants
of varying gestations, given once daily gentamicin.
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